Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 04, 2025 07:07 ET | Source: DIAGONAL THERAPEUTICS, INC

Diagonal Therapeutics Initiates Natural History Study of Adults Living with Hereditary Hemorrhagic Telangiectasia (HHT), a Rare Bleeding Disorder with No Approved Treatments

Diagonal Therapeutics today announced the initiation of a natural history study for HHT in partnership with patient advocacy group Cure HHT.
December 03, 2024 07:00 ET | Source: DIAGONAL THERAPEUTICS, INC

Diagonal Therapeutics to Present Data at ASH 2024 Demonstrating the Economic and Clinical Burden of Hereditary Hemorrhagic Telangiectasia (HHT)

Diagonal Therapeutics to Present Data at ASH 2024 Demonstrating the Economic and Clinical Burden of Hereditary Hemorrhagic Telangiectasia (HHT)
October 08, 2024 07:00 ET | Source: DIAGONAL THERAPEUTICS, INC

Diagonal Therapeutics to Present at the Cure HHT’s 15th International Scientific Conference

Diagonal Therapeutics to Present at the Cure HHT’s 15th International Scientific Conference
April 03, 2024 06:00 ET | Source: DIAGONAL THERAPEUTICS, INC

Diagonal Therapeutics Launches with $128 Million in Financing to Pioneer a New Approach to Discovering and Developing Agonist Antibodies to Tackle the Underlying Causes of Severely Debilitating Diseases

Diagonal Therapeutics Launches with $128 Million in Financing to Pioneer a New Approach to Discovering and Developing Agonist Antibodies